Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX

BACKGROUND/AIMS: There has been growing evidence on the utility of neoadjuvant FOLFIRINOX in borderline resectable (BR) or locally advanced (LA) pancreatic cancer. However, factors predicting survival in these patients remain to be identified, and we aimed to identify these prognostic factors. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Young Hoon, Lee, Sang Hyub, You, Min Su, Shin, Bang Sup, Paik, Woo Hyun, Ryu, Ji Kon, Kim, Yong-Tae, Kwon, Wooil, Jang, Jin-Young, Kim, Sun-Whe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960979/
https://www.ncbi.nlm.nih.gov/pubmed/32235008
http://dx.doi.org/10.5009/gnl19182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960979/
https://www.ncbi.nlm.nih.gov/pubmed/32235008
http://dx.doi.org/10.5009/gnl19182

Ejemplares similares